Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | Director · President, CEO, COB · 10% owner | October 06, 2025 | October 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date October 06, 2025 · Filed October 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 187,497 |
Reported balance
After 2025-10-06 transaction · row 1
1 source rowRow 1 · 2025-10-06 · Grant · Acquired 15,625 · Balance 187,497 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2030-10-08 | Direct | 11,719 |
Reported balance
After 2025-10-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-10-06 · Grant · Acquired 11,719 · Balance 11,719 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-08-18 | Direct | 293,479 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 293,479 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 42,059 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 42,059 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 106,762 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 106,762 F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 438,596 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 438,596 F3: The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2035-02-14 | Direct | 791,885 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 791,885 F4: The options vests and becomes exercisable to the extent of 395,943 shares on February 14, 2025 and 395,942 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F3: The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
F4: The options vests and becomes exercisable to the extent of 395,943 shares on February 14, 2025 and 395,942 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2025 Filed Oct 20, 2025 12:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 11,719 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001021771-25-000140 · form4.xml · derivative · entry 7 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,719 Underlying: Common Stock · 11,719 shares Expires 2030-10-08 Read SEC document |
| October 06, 2025 Filed Oct 20, 2025 12:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 15,625 | $1.60 | $25,000.00 |
DisclosureSEC source: 0001021771-25-000140 · form4.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,497 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:22 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 791,885 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001021771-25-000036 · form4.xml · derivative · entry 6 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 791,885 Underlying: Common Stock · 791,885 shares Expires 2035-02-14 F4 · derivative.exercise_date: The options vests and becomes exercisable to the extent of 395,943 shares on February 14, 2025 and 395,942 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:36 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Tax withholdingCommon Stock | 17,633 | $1.39 | $24,509.87 |
DisclosureSEC source: 0001021771-24-000077 · form4.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,872 F1 · kind: Shares were withheld from vested stock grant to pay the associated withholding taxes. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 438,596 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001021771-24-000044 · form4.xml · derivative · entry 5 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 438,596 Underlying: Common Stock · 438,596 shares Expires 2034-02-13 F5 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 219,298 shares on February 13, 2024 and 219,298 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested. Read SEC document |
| September 15, 2023 Filed Sep 18, 2023 13:17 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,200 | $1.70 | $3,740.00 |
DisclosureSEC source: 0001021771-23-000096 · form4.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,505 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.66 to $1.75 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. Read SEC document |
| September 13, 2023 Filed Sep 13, 2023 21:00 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 800 | $1.53 | $1,226.00 |
DisclosureSEC source: 0001021771-23-000090 · form4.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,105 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.52 to $1.54 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. Read SEC document |
| September 06, 2023 Filed Sep 6, 2023 21:53 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,887 | $1.96 | $5,658.52 |
DisclosureSEC source: 0001021771-23-000088 · form4.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,305 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.93 to $2.02 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. Read SEC document |
| July 25, 2023 Filed Jul 25, 2023 21:56 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 4,200 | $2.44 | $10,248.00 |
DisclosureSEC source: 0001140361-23-036103 · form4.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,418 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.41 to $2.47 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:47 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Tax withholdingCommon Stock | 6,729 | $2.92 | $19,648.68 |
DisclosureSEC source: 0001021771-23-000026 · form4.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,218 F1 · kind: Shares were withheld from vested stock grant to pay the associated withholding taxes. F2 · balance_after: Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. Read SEC document |
| February 18, 2023 Filed Feb 27, 2023 22:17 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Tax withholdingCommon Stock | 374 | $2.99 | $1,118.26 |
DisclosureSEC source: 0001567619-23-003875 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,947 F1 · kind: Shares were withheld from vested stock grant to pay the associated withholding taxes. F2 · balance_after: Includes 98,862 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 22:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 106,762 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001567619-23-003324 · doc1.xml · derivative · entry 4 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,762 Underlying: Common Stock · 106,762 shares Expires 2033-02-17 F4 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 with the remaining 53,381 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 19:49 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 400 | $3.10 | $1,241.36 |
DisclosureSEC source: 0001567619-23-001697 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,321 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.07 to $3.12 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| January 27, 2023 Filed Jan 30, 2023 14:33 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 200 | $3.01 | $602.00 |
DisclosureSEC source: 0001567619-23-001399 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,921 F1 · balance_after: Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 17:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $3.17 | $317.00 |
DisclosureSEC source: 0001567619-23-001186 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,721 F1 · balance_after: Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 17:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $3.10 | $310.00 |
DisclosureSEC source: 0001567619-23-001186 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,621 F1 · balance_after: Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 13:19 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $3.09 | $308.70 |
DisclosureSEC source: 0001567619-23-001056 · doc1.xml · nonDerivative · entry 3 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,521 F1 · balance_after: Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 13:19 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $3.10 | $309.60 |
DisclosureSEC source: 0001567619-23-001056 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,421 F1 · balance_after: Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 13:19 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 200 | $3.13 | $626.00 |
DisclosureSEC source: 0001567619-23-001056 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,321 F1 · balance_after: Includes 99,899 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 23:06 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $3.08 | $308.00 |
DisclosureSEC source: 0001567619-23-000770 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,121 F1 · price: Includes 100,935 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,036 shares on January 18, 2023, 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. F1 · balance_after: Includes 100,935 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,036 shares on January 18, 2023, 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 13:22 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $2.99 | $299.00 |
DisclosureSEC source: 0001567619-22-022055 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,021 F1 · balance_after: Includes 100,935 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,036 shares on January 18, 2023, 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 13:22 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 200 | $3.02 | $604.00 |
DisclosureSEC source: 0001567619-22-022055 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,921 F1 · balance_after: Includes 100,935 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,036 shares on January 18, 2023, 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| December 07, 2022 Filed Dec 7, 2022 23:04 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,800 | $2.99 | $5,374.98 |
DisclosureSEC source: 0001567619-22-021408 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,721 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.93 to $3.00 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 101,972 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on December 18, 2022 and February 18, 2023, 1,036 shares on January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 12:49 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,000 | $2.88 | $2,876.50 |
DisclosureSEC source: 0001567619-22-020651 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,921 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.80 to $2.97 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 101,972 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on December 18, 2022 and February 18, 2023, 1,036 shares on January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:16 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 42,059 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001567619-22-019187 · doc1.xml · derivative · entry 5 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,059 Underlying: Common Stock · 42,059 shares Expires 2031-11-04 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F3 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:16 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 42,059 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-22-019187 · doc1.xml · derivative · entry 4 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,059 shares Expires 2031-11-04 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F3 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:16 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 293,479 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001567619-22-019187 · doc1.xml · derivative · entry 3 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,479 Underlying: Common Stock · 293,479 shares Expires 2031-03-18 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F2 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:16 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 293,479 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-22-019187 · doc1.xml · derivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 293,479 shares Expires 2031-03-18 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F2 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested. Read SEC document |
| September 22, 2022 Filed Sep 23, 2022 13:55 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $2.85 | $285.00 |
DisclosureSEC source: 0001567619-22-017754 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,921 F1 · balance_after: Includes 104,045 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| September 22, 2022 Filed Sep 23, 2022 13:55 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $2.99 | $299.00 |
DisclosureSEC source: 0001567619-22-017754 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,821 F1 · balance_after: Includes 104,045 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| July 12, 2022 Filed Jul 13, 2022 12:25 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 700 | $2.95 | $2,065.00 |
DisclosureSEC source: 0001567619-22-013928 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,721 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.90 to $2.97 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 107,154 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 13:20 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,100 | $3.10 | $3,407.91 |
DisclosureSEC source: 0001567619-22-013553 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,021 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.03 to $3.1499 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 107,154 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 600 | $3.73 | $2,238.00 |
DisclosureSEC source: 0001567619-22-013067 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,921 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.57 to $3.86 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 15, 2022 Filed Jun 15, 2022 21:30 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 700 | $3.68 | $2,577.54 |
DisclosureSEC source: 0001567619-22-012910 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,321 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.655 to $3.7167 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 15:01 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 500 | $3.91 | $1,955.95 |
DisclosureSEC source: 0001567619-22-012867 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,621 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.8499 to $3.9699 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 15:55 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $3.92 | $392.00 |
DisclosureSEC source: 0001567619-22-012812 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,121 F1 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 15:55 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $3.98 | $398.00 |
DisclosureSEC source: 0001567619-22-012812 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,021 F1 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 15:41 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $4.28 | $428.00 |
DisclosureSEC source: 0001567619-22-012581 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,921 F1 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 10:58 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 200 | $4.60 | $920.00 |
DisclosureSEC source: 0001567619-22-012211 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,821 F1 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| May 26, 2022 Filed May 27, 2022 14:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,700 | $3.52 | $9,494.01 |
DisclosureSEC source: 0001567619-22-011807 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,621 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.4347 to $3.5499 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| May 02, 2022 Filed May 2, 2022 21:14 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 200 | $3.96 | $791.80 |
DisclosureSEC source: 0001567619-22-009300 · doc1.xml · nonDerivative · entry 2 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,921 F1 · balance_after: Includes 109,227 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares beginning on May 18, 2022 and continuing monthly through September 18, 2022, 1,036 shares beginning on October 18, 2022 and continuing monthly through February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| May 02, 2022 Filed May 2, 2022 21:14 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 200 | $3.94 | $787.00 |
DisclosureSEC source: 0001567619-22-009300 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,721 F1 · balance_after: Includes 109,227 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares beginning on May 18, 2022 and continuing monthly through September 18, 2022, 1,036 shares beginning on October 18, 2022 and continuing monthly through February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 21:08 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 12,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-007347 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,521 F1 · price: Shares received pursuant to a restricted stock unit grant. Vests in twelve nearly equal monthly installments beginning April 18, 2022. F2 · balance_after: Includes 110,264 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares beginning on April 18, 2022 and continuing monthly through September 18, 2022, 1,036 shares beginning on October 18, 2022 and continuing monthly through February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| January 24, 2022 Filed Jan 24, 2022 22:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,470 | $3.40 | $4,998.00 |
DisclosureSEC source: 0001567619-22-001588 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,083 F1 · balance_after: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. Read SEC document |
| January 05, 2022 Filed Jan 5, 2022 21:52 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,000 | $3.85 | $7,700.00 |
DisclosureSEC source: 0001567619-22-000585 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,613 F1 · balance_after: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 15:00 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 799 | $5.50 | $4,394.50 |
DisclosureSEC source: 0001567619-21-021415 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,613 F1 · balance_after: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. Read SEC document |
| November 23, 2021 Filed Nov 23, 2021 22:15 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $6.00 | $15,000.00 |
DisclosureSEC source: 0001567619-21-021072 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,814 F1 · balance_after: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. Read SEC document |
| November 22, 2021 Filed Nov 22, 2021 22:29 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 396 | $6.31 | $2,498.76 |
DisclosureSEC source: 0001567619-21-020992 · doc1.xml · nonDerivative · entry 1 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,314 F1 · balance_after: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 23:07 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,500 | $6.51 | $9,765.00 |
DisclosureSEC source: 0001567619-21-020595 · doc1.xml · nonDerivative · entry 4 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,918 F2 · balance_after: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 23:07 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 200 | $6.55 | $1,310.00 |
DisclosureSEC source: 0001567619-21-020595 · doc1.xml · nonDerivative · entry 3 ALSTODT LANCE · CIK 0001756228 · Director · President, CEO, COB 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,418 F2 · balance_after: Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.